

Milk antibody response after 3rd dose of COVID-19 mRNA vaccine and SARS-CoV-2 breakthrough infection and implications for infant protection

Yarden Golan, Ph.D.¹, Mikias Ilala^{2,3}, Caryl Gay Ph.D.⁴, Soumya Hunagund⁵, Christine Y. Lin⁵, Arianna G. Cassidy, M.D.⁵, Unurzul Jigmeddagva, M.D.⁶, Lin Li, M.D., Ph.D.^{5,6}, Nida Ozarslan M.D.⁵, Ifeyinwa V. Asiodu, Ph.D, R.N.⁴, Nadav Ahituv, Ph.D.¹, Valerie J. Flaherman, M.D., M.P.H.², Stephanie L. Gaw, M.D., Ph.D.^{5,6*} Mary Prah, M.D.^{2,7*}

Author Affiliations

¹ Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, and Institute for Human Genetics, University of California, San Francisco, California, United States of America.

² Department of Pediatrics, University of California, San Francisco, California, United States of America.

³ Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, California, United States of America.

⁴ Department of Family Health Care Nursing, University of California, San Francisco, California, United States of America.

⁵ Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.

⁶ Center for Reproductive Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.

⁷ Division of Pediatric Infectious Diseases and Global Health, University of California, San Francisco, California, United States of America.

*Co-corresponding authors:

Stephanie L. Gaw- Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, 513 Parnassus Ave, HSE16, Box 0556, San Francisco, CA 94143. Phone: 415.476.0535. Email: Stephanie.Gaw@ucsf.edu

Mary Prah- Division of Pediatric Infectious Diseases and Global Health, Department of Pediatrics, University of California San Francisco, 550 16th St. 4th Floor. San Francisco, CA 94158. Phone (415) 514-0510, Email: mary.prah@ucsf.edu

Conflict of interest:

The authors have declared that no conflict of interest exists.

Funding:

Y.G. was supported by the Weizmann Institute of Science -National Postdoctoral Award Program for Advancing Women in Science, and of the Human Frontiers in Science Program (HFSP). M.P. was supported by the National Institutes of Health (NIAID K23AI127886), the Marino Family Foundation, and UCSF REAC award. S.L.G. was supported by the National Institutes of Health (NIAID K08AI141728).

Authors contribution:

YG, MP, and SLG designed the study. YG and MI conducted experiments. YG, acquired data, analyzed data, and was lead author of the manuscript. CG analyzed data, conducted statistical analysis assisted with editing the manuscript. SH and AC recruited participants, acquired data, and assisted with editing the manuscript. UJ, LL, NO, CYL collected samples and conducted experiments. IVA assisted with study and questionnaires design and editing and writing the manuscript. NA supervised the study and assisted in writing the manuscript. SLG and VJF designed and supervised the study and assisted in writing the manuscript. MP analyzed data, assisted with editing and writing the manuscript. YG, MP, SLG acquire funding for the study.

Abstract:

Anti-SARS-CoV-2 antibodies have been found in human-milk after COVID-19 infection and vaccination. However, little is known about their persistence in milk after booster vaccination and breakthrough infection. In this study, human-milk, saliva and blood samples were collected from 33 lactating individuals before and after mRNA-based vaccination and COVID-19 breakthrough infections. Antibody levels were measured using ELISA and symptoms were assessed using questionnaires. Evaluation of maternal and infant symptomatology revealed that infected mothers reported more symptoms than vaccinated mothers. We found that after vaccination, human-milk anti-SARS-CoV-2 antibodies persisted for up to 8 months. In addition, distinct patterns of human milk IgA and IgG production we observed after breakthrough infection compared to 3-dose vaccination series alone, indicating a differential central and mucosal immune profiles in hybrid compared with vaccine-induced immunity. To investigate passively-derived milk antibody protection in infants, we examined the persistence of these antibodies in infant saliva after breastfeeding. We found that IgA was more abundant in infant saliva compared to IgG and persist in infant saliva longer after feeding. Our results delineate the differences in milk antibody response to vaccination as compared to breakthrough infection and emphasize the importance of improving the secretion of IgA antibodies to human milk after vaccination to improve the protection of breastfeeding infants.

Introduction: Exclusive breastfeeding is recommended for infants up to 6 months of age and is recommended by the American Academy of Pediatrics to be continued with the introduction of complementary foods to the infant diet for 2 years of age or longer [1]. Breastfeeding provides short and long-term protective effects from a number of diseases [1] and breastfeeding duration and exclusivity is specifically associated with reduced risk of lower respiratory tract infections in infants [2]. Human milk contains multiple factors that provide anti-viral protection to the infant including immune cells, extracellular vesicles, cytokines, enzymes and antibodies [3–5]. The breast is a unique organ in that despite not having a direct mucosal surface, it provides passive mucosal immunity including IgA, IgM, and IgG to the breastfeeding infant. IgA, the predominant human milk antibody, is typically present in its secretory form (sIgA) and provides passive mucosal defense for the infant’s respiratory and digestive systems [5–7]. In contrast, IgG, despite being the most prominent antibody in blood, is present in its monomeric form in human milk at lower levels than IgA or IgM, and helps provide protection against enteric pathogens [8,9]. Numerous studies have shown the presence of anti-SARS-CoV-2 antibodies in human milk after two doses of mRNA-based COVID-19 vaccines [10–21]. Specifically, IgA and IgG against the spike (S) protein of SARS-CoV-2 have been found in human milk after both vaccination and infection [7]. However, differential antibody dynamics based on the type of preceding antigen exposure — vaccination versus infection— has been described. Milk IgG increases significantly after the 2nd vaccine dose, while secretory IgA significantly rises after SARS-CoV-2 infection with minimal increase of IgG [16,18]. As the COVID-19 pandemic and vaccine strategies have evolved over time, further information is needed on the potency and duration of the antibody response in milk beyond the 2nd vaccine dose and the impact of hybrid immunity from breakthrough infections that have become increasingly common in the Omicron era.

Young infants are increased risk of severe disease and hospitalization from COVID-19 as compared to older children [22]. Current COVID-19 vaccinations are not approved until infants reach at least 6 months of age. Vaccination during pregnancy may provide some protection to the infant, as infants that were born to fully vaccinated mothers have a lower risk for COVID-19 infection[23] and hospitalization [24]. However, due to the lack of inclusion of lactating individuals in COVID-19 vaccination clinical trials, there is limited data on symptomatology and immune protection following vaccination and infection in lactating individuals and breastfeeding infants. Further information is needed on immune protection against COVID-19 during the vulnerable first months of infancy including the persistence of anti-SARS-CoV-2 antibodies in milk after vaccination and level of antibody transfer to the infant.

Here, we present longitudinal assessment of anti-SARS-CoV-2 milk antibody levels of lactating individuals after 2- or 3-dose vaccine series, as well as following breakthrough infection in vaccinated mothers. We assessed maternal and infant symptomatology after vaccination or infection. Lastly, we assessed the presence and duration of passively transferred antibodies in the saliva of breastfeeding infants.

Results:

Participant cohort: Human milk samples were collected from 33 lactating individuals that received the first 2 doses of an mRNA-based COVID-19 vaccine (BTN162b2 or mRNA-1273) during pregnancy (n=25) or lactation (n=8) (**Table 1**). Twenty-six individuals from this cohort received the 3rd dose of COVID-19 vaccine and reported their symptoms after vaccination (**Table 2**). Out of the 26 participants receiving 3rd dose, 19 participants (3rd dose subgroup) provided samples for antibodies assessment after 3rd dose and their clinical characteristics are shown in **Table 3**. Of these 19 participants that received a 3rd dose, 10 experienced a breakthrough infection from December 2021-March 2022, during the Omicron wave (SARS-CoV-2 B.1.1.529) in the San Francisco Bay Area (**Table 3**). Additional fourteen participants provided milk and/or saliva and infant saliva samples (after 2nd or 3rd dose).

Symptomatology following 3rd mRNA vaccine dose and/or COVID-19 infection: Patient reported symptoms were collected by REDCap surveys at least 2 weeks after exposure to a 3rd mRNA vaccine dose and/or breakthrough infection. No severe symptoms were reported after the 3rd vaccine dose in this cohort (**Table 2**). The most common maternal symptoms were pain in the injection site (reported by 62% of participants) or fatigue and tiredness (reported by 50% of participants). Maternal post 3rd dose symptoms were significantly lower compared to symptoms reported in similar cohort of lactating individuals after 2nd dose [12], and were not significantly different from reports after 1st dose (**Figure 1**). In addition, symptoms reported in our cohort were similar to rates reported in larger cohorts [26]. When comparing post 3rd dose and post-infection symptoms of the individuals with breakthrough infection in this cohort (n=10) we found that general symptoms were more likely to be reported by these participants after COVID-19 infection than after the 3rd dose (p=0.025 for McNemar's chi-square test) (**Table 4**). No infant symptoms were reported by mothers after receiving the 3rd dose (n=26); however, all infants that were infected with COVID-19 at the time of this study (n=8) had at least one symptom reported, including cough, runny nose, and fever (**Table 5**). No infants were hospitalized after COVID-19 infection in this cohort, but one infant required evaluation in the Emergency Department for their COVID-19 infection. Additionally, in seven of eight infected infants, surveyed mothers reported consultation with their physician about the infant's COVID-19 infection (**Table 5**). The infected infants were on average 8 months old (range 5-12 months) and were not exclusively breastfed at this age (supplemented with formula or with complementary foods).

Longitudinal persistence of anti-SARS-CoV-2 milk antibodies after vaccination and differential milk IgA responses following breakthrough COVID-19 infection compared to post-vaccination

Milk anti-Spike antibodies were detected 6-8 months following the 2nd dose, but milk Spike IgG significantly decreased over time — with only 52% (10 of 19) of individuals had detectable antibodies in milk prior to 3rd dose boost vaccination. (**Figure 2A**). In contrast to IgG, 16 of 19 (84%) of individuals maintained detectable levels of milk anti-Spike IgA after the 2nd dose, and prior to 3rd dose boosting, but there was also a significant decrease in these antibody levels over time (**Figure 2B**). After the 3rd dose, milk anti-Spike IgG levels increased significantly, and were significantly higher compared to their levels following the 2nd dose (**Figure 2A**). Milk anti-Spike

IgA levels also trended higher after receipt of the 3rd dose but was not statistically significantly increased over pre-boost levels and their levels were similar to the post 2nd dose timepoint indicating a persistence of anti-Spike milk IgA over time after primary vaccination series, but a lack of significant boosting of milk anti-Spike IgA levels after the 3rd dose. Both IgG and IgA levels decreased 5 months after the 3rd dose, but in contrast to the pre-boost timepoint all participants had detectable IgG levels and only 3 of 5 (60%) had detectable IgA levels at this time point (**Figure 2A and 2B**). Individuals with breakthrough SARS-CoV-2 infection after their 3rd dose had significantly higher levels of IgA in their milk following infection (**Figure 2B**) compared to individuals after 2nd and 3rd vaccine doses. However, milk anti-Spike IgG levels after infection were comparable to the levels after 3rd dose (**Figure 2A**). Furthermore, we found higher levels of anti-Spike IgA antibodies in the plasma of lactating individuals after infection compared to after the 3rd dose (**Figure 2C**). There was also a positive correlation between anti-Spike IgA antibodies levels in milk and maternal plasma after the 3rd dose ($r=0.8091$ and $p=0.0039$ **Figure 2D**), and the correlation between milk and blood IgA levels was even stronger after infection ($r=0.937$ and p -value 0.0006).

Persistence of maternal milk-derived SARS-CoV-2 antibodies in infant saliva after breastfeeding: Milk antibodies may provide protection to the infant at the oropharyngeal mucosal surfaces, but little is known regarding the stability of these antibodies in the infant mouth after breastfeeding. To answer this question, we investigated the stability and persistence of milk antibodies in infant saliva after breastfeeding using saliva samples collected from infants at multiple time points after feeding. We compared these to antibody levels in maternal milk and saliva samples collected the same day as the infant. We found a positive correlation between anti-Spike IgA levels in milk and maternal saliva samples (**Figure 3A**), as well as a positive but non-significant correlation for milk and maternal saliva anti-Spike IgG antibodies (**Figure 3B**). We next evaluated infant saliva samples collected after feeding by mothers who had detectable anti-Spike IgG or IgA in their milk. Anti-Spike IgA levels were found to be significantly higher in infant saliva over time after feeding compared to IgG antibodies, with 6/11 (55%) infants having detectable antibodies immediately after breastfeeding and 3/11 (27%) infants remaining positive at all time points until the next feeding. We found that IgG antibodies were less abundant in the infant's saliva after feeding, with all except one infant's samples below the assay cut-off (**Figure 3C and 3D**). Of note, we could not identify any correlation between infant age or lactation exclusivity to infant saliva antibodies, which might be due to the small sample size of this study.

Discussion:

We found that mRNA-based vaccines administered in pregnancy or during lactation stimulated increased anti-SARS-CoV-2 antibody (specifically anti-Spike antibody) levels in human milk that persisted for up to 8 months after vaccination. In addition, we found that a 3rd dose (booster) significantly increased the IgG antibody levels in milk. These findings highlight the importance of vaccine boosting during pregnancy and lactation in providing additional transfer of antibodies through human milk, which may provide protection against SARS-CoV-2 to young infants, who are currently not eligible for COVID-19 vaccination until they reach 6 months of age.

In addition, we performed a comparative analysis of anti-Spike milk IgG and IgA levels that are induced after 2 doses vs 3 doses of the mRNA vaccine, as well as SARS-CoV-2 breakthrough infection. Although anti-SARS-CoV-2 IgA antibodies are induced after vaccination, their levels are significantly boosted after natural infection as compared to vaccination alone. In contrast, milk anti-SARS-CoV-2 IgG levels did not significantly increase after breakthrough infection. Of note, milk IgG levels were very high after the 3rd dose and may have already reached peak levels at the time of breakthrough infections, which occurred within 7 weeks of the 3rd dose in our cohort. Previous studies have also shown similar patterns of IgA in milk and saliva [27,28], indicating that exposure to SARS-CoV-2 infection has a greater effect on mucosal IgA secretion compared to vaccination. Interestingly, mucosal and systemically-delivered influenza vaccines result in similar increases in influenza specific IgA antibodies in milk [29] suggesting that factors in addition to exposure location may affect the production of milk IgA antibodies.

IgA antibodies play a critical role in humoral immune response and virus neutralization, with peripheral expansion of IgA plasmablasts found in SARS-CoV-2 infected patients shortly after the onset of symptoms [30]. Our results demonstrate a positive correlation between maternal IgA levels in milk and plasma, as well as milk and saliva. Previous studies have shown that mucosal immunity in the bronchoalveolar lavage fluid is weaker after vaccination compared to post-infection immunity [31]. In addition, COVID-19 infection prior to vaccination was shown to induce a better secretion of antigen-specific mucosal secretory IgA to the saliva, compared to vaccination alone [32]. Our findings further suggest that mRNA-vaccines induced an IgA response in milk and in blood, but to a lower extent compared to hybrid immunity from vaccination and COVID-19 infection. To the best of our knowledge, our work is the first to compare boosting of milk antibody levels after the 3rd dose versus infection during the time that the Omicron variant was the predominant circulating strain.

In addition, we found that IgA antibodies are more abundant in infant saliva at multiple time points after breastfeeding compared to IgG; therefore, developing vaccines that improve the secretion of IgA antibodies to milk (and other mucosal organs) might also better contribute to infant (and mother) protection against infection. Larger studies are needed to evaluate the protective effects of anti-SARS-CoV-2 milk-derived antibodies on breastfed infants.

Eight infants in our cohort were infected with SARS-CoV-2 during the study period (when the Omicron variant was predominant [33]), in the setting of maternal infection, despite their mother having received the 3rd vaccine dose. Regardless of the persistence of anti-SARS-CoV-2 antibodies in milk over time, passively derived milk antibodies alone were insufficient to fully protect against infection, possibly due to immune evasion from vaccine-induced antibodies by the Omicron variant, and/or weaker protection provided by milk antibodies compared to passively-acquired transplacentally transferred IgG systemic antibodies that wane after birth [34,35]. All infants infected in this cohort were older than 5 months, so their transplacental antibodies were lower or absent at time of infection, and most of them were not exclusively breastfed when infected (were supplemented with baby formula or complementary foods). However, due to our limited sample size, we were unable to assess the level of protection provided by transfer of vaccine-related antibodies in human milk, as compared to infants with no SARS-CoV-2 vaccine-related milk antibodies. The Center for Disease Control and Prevention

(CDC) reported that during the early 2022 Omicron variant peak, infants hospitalization rates were 5 times higher compared to during the Delta variant peak [22]. All COVID-19 infected infants in this cohort presented with symptoms, and one infant was admitted for evaluation in emergency care unit for COVID-19 symptoms. These results underscore the importance of both passive maternally-derived and early infancy vaccination protection for this vulnerable infant population. In contrast to infant infected with SARS-CoV-2, no infants in our cohort were reported to have symptoms following maternal COVID-19 vaccination during lactation. In a larger cohort which examined 10,278 participants after 3rd dose, 1.2% of mothers reported any issue in their infant after vaccination during lactation [26]. These reports emphasize the importance of including lactating individuals in clinical trials, to be able to examine the direct effect of vaccine administration on infant symptoms, in compared to placebo group, which are currently absent.

In summary, we found that human milk antibody levels increase significantly after the 2nd vaccine dose and can maintain high levels in milk up to 8 months post vaccination in some individuals. Boosting with a 3rd vaccine dose significantly increases IgG antibody levels that remain elevated for at least an additional 5 months post-booster vaccination in milk. Milk IgA antibodies were much more significantly increased after breakthrough SARS-CoV-2 infection, compared to vaccination alone. It is specifically important as based on our results, IgA as compared to IgG antibodies were more stable in the infant mouth after feeding — and may be more important in infant protection against SARS-CoV-2 infection. Further large-scale cohort studies of vaccinated lactating individuals are needed to better understand the role of milk antibodies in infant protection from COVID-19 infection. Future vaccine development should focus on the induction of milk IgA antibodies to enhance infant protection during lactation.

Methods:

Participant cohort and data collection- The institutional review board of the University of California, San Francisco, approved the study (#21-33621). Written informed consent was obtained from all study volunteers as part of the COVID-19 Vaccine in Pregnancy and Lactation (COVIPAL) cohort study. Pregnant or lactating mRNA COVID-19 vaccination recipients were enrolled from December 2020 to April 2022. Clinical data and symptoms were collected by medical record review and REDCap questionnaires and characterized in **Table 1**. Participants were surveyed following each COVID-19 vaccine dose, which included questions about maternal and infant symptomology after maternal 3rd dose. In February 2022 all COVIPAL participants were surveyed if they had a new diagnosis of SARS-CoV-2 infection since the last vaccine dose and if the participant was willing to provide post-infection biospecimen samples. Individuals with SARS-CoV-2 breakthrough infection (confirmed by PCR or rapid antigen testing) were administered questionnaires to capture maternal and infant post infection symptoms. For individuals at the time of post infection survey that had not yet completed their 3rd dose questionnaire, their 3rd dose symptoms were captured at the same time of their post infection symptoms (up to 6 months after receiving the 3rd vaccine dose). No infants were vaccinated during the study period.

Milk sample collection and processing- Milk samples were collected at the following time points: 1) Pre-vaccine 2) Post-Dose 2 (range 4.7 to 7 weeks following 2nd dose; 3) Pre-Boost (prior to 3rd dose, range 26-37 weeks following 2nd dose); 4) Post-Dose 3 (range 4-10 weeks following 3rd dose; 5) 5 months after Post-Dose 3 (range 18-21 weeks after 3rd dose) and 6) Post-Infection (range 2-7 weeks following breakthrough infection accruing after 3-dose vaccination series). Fresh human milk samples were self-collected by participants into sterile containers. Milk samples were either processed immediately by the study staff or frozen by mothers in their home freezer as soon as possible after pumping. Samples were transported on ice from participant's home to the lab for processing. Milk was aliquoted and stored at -80°C until analyzed.

Blood sample collection and processing- Paired maternal blood samples were collected at the same time points as described above for milk samples from a subset of participants (n=18). Whole blood was collected into EDTA tubes. Plasma was isolated from whole blood by centrifugation and immediately cryopreserved at -80°C until analysis.

Infant and maternal saliva sample collection- To evaluate the duration of persistence of antibodies in the infant's mouth after breastfeeding, we collected saliva samples from breastfeeding infants at the following timepoints: 1) immediately after breastfeeding 2) 30 min after breastfeeding 3) 60 min after breastfeeding and 4) before next breastfeeding (2-3 hours after feeding). Paired maternal saliva and milk samples were collected from the infant's mother on the day of infant collection (n=11). Maternal saliva samples were collected with OraSure collection kits by placing the swab in the mouth for 5 minutes until saturated. For infant saliva samples, sponges for assisted saliva collection were used and were inserted to OraSure collection tubes (Product CS-2, DNAGenotek Inc, Ontario, Canada).

ELISA assay- Anti-Spike ELISA assay (Euroimmune, Germany) was used to measure IgA and/or IgG levels in blood, skim milk, and saliva samples. Plasma and skim milk samples were thawed on ice. After thawing, milk fat was separated by cold centrifugation (10,000g for 10 min, 4°C) and diluted 1:4 with the provided diluent buffer, and examined using the manufacturer's protocol as described, with an additional blocking step with 5% BSA in TBS with 0.5% Tween 20 for 30 min before loading the samples as recommended to increase specificity [25]. Plasma samples were diluted 1:101 and were examined by the same protocol as milk samples. OD values of samples were calculated by dividing by the calibrator OD value (provided with the kit); values with sample:calibrator ratio greater than 1 were considered positive. Saliva samples were concentrated using Amicon Ultra Centrifugal Filters (UFC5199BK, Millipore Sigma, USA), as previously described [25]. Milk samples were analyzed in duplicate; and saliva samples were analyzed once for each antibody (IgA and IgG) due to limited sample availability.

Statistical analysis- Spearman analysis was used for correlation between milk and maternal saliva antibodies levels. Mann-Whitney test was used to evaluate differences between the different time points in milk and plasma antibody levels. Wilcoxon matched-pairs signed rank test was used to compared IgA and IgG levels in infant saliva at the different time points. Comparison of symptoms reported by each participant after 3rd dose and after infection was performed by McNemar's chi-square test. Fisher's Exact test was used to compared post

vaccine symptoms after 1, 2 or 3 doses. Data about 1st and 2nd dose were previously reported [12]. Statistical analysis was performed using Prism version 9.1.0 (GraphPad) and Stata Version 15.0 were used for analyses.

References:

- [1] Meek JY, Noble L, Section on Breastfeeding. Policy Statement: Breastfeeding and the Use of Human Milk. *Pediatrics* 2022;150. <https://doi.org/10.1542/peds.2022-057988>.
- [2] Quigley MA, Carson C, Sacker A, Kelly Y. Exclusive breastfeeding duration and infant infection. *Eur J Clin Nutr* 2016;70:1420–7.
- [3] Morniroli D, Consales A, Crippa BL, Vizzari G, Ceroni F, Cerasani J, et al. The antiviral properties of human milk: A multitude of defence tools from mother nature. *Nutrients* 2021;13:694.
- [4] Vassilopoulou E, Feketea G, Koumbi L, Mesari C, Berghea EC, Konstantinou GN. Breastfeeding and COVID-19: From nutrition to immunity. *Front Immunol* 2021;12:661806.
- [5] Atyeo C, Alter G. The multifaceted roles of breast milk antibodies. *Cell* 2021;184:1486–99.
- [6] Albrecht M, Arck PC. Vertically transferred immunity in neonates: Mothers, mechanisms and mediators. *Front Immunol* 2020;11:555.
- [7] Hunagund S, Golan Y, Asiodu IV, Prah M, Gaw SL. Effects of vaccination against influenza, pertussis, and COVID-19 on human milk antibodies: current evidence and implications for health equity. *Front Immunol* 1AD;0. <https://doi.org/10.3389/fimmu.2022.910383>.
- [8] Caballero-Flores G, Sakamoto K, Zeng MY, Wang Y, Hakim J, Matus-Acuña V, et al. Maternal immunization confers protection to the offspring against an attaching and effacing pathogen through delivery of IgG in breast milk. *Cell Host Microbe* 2019;25:313-323.e4.
- [9] Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. *Cell Res* 2020;30:492–506.
- [10] Narayanaswamy V, Pentecost BT, Schoen CN, Alfandari D, Schneider SS, Baker R, et al. Neutralizing antibodies and cytokines in breast milk after Coronavirus disease 2019 (COVID-19) mRNA vaccination. *Obstet Gynecol* 2022;139:181–91.
- [11] Low JM, Gu Y, Ng MSF, Amin Z, Lee LY, Ng YPM, et al. Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees. *Npj Vaccines* 2021 6:1 2021;6:1–8.
- [12] Golan Y, Prah M, Cassidy AG, Gay C, Wu AHB, Jigmeddagva U, et al. COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads. *Frontiers in Immunology* 2021;12:4596.
- [13] Armistead B, Jiang Y, Carlson M, Ford ES, Jani S, Houck J, et al. Mucosal memory T cells in breastmilk are modulated by SARS-CoV-2 mRNA vaccination. *BioRxiv* 2021. <https://doi.org/10.1101/2021.12.03.21267036>.
- [14] Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. COVID-19 vaccine response in pregnant and lactating women: a cohort study. *American Journal of Obstetrics and Gynecology* 2021;0:2021.03.07.21253094.
- [15] Perl SH, Uzan-Yulzari A, Klainer H, Asiskovich L, Youngster M, Rinott E, et al. SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women. *JAMA* 2021:2013–4.
- [16] Pace RM, Williams JE, Järvinen KM, Belfort MB, Pace CDW, Lackey KA, et al. Characterization of sars-cov-2 rna, antibodies, and neutralizing capacity in milk produced by women with covid-19. *MBio* 2021;12:1–11.

- [17] Demers-Mathieu V, Dung M, Mathijssen GB, Sela DA, Seppo A, Järvinen KM, et al. Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk. *Journal of Perinatology* 2020:1–10.
- [18] Fox A, Marino J, Amanat F, Krammer F, Hahn-Holbrook J, Zolla-Pazner S, et al. Robust and specific secretory IgA against SARS-CoV-2 detected in human milk. *iScience* 2020;23:101735.
- [19] Beharier O, Plitman Mayo R, Raz T, Nahum Sacks K, Schreiber L, Suissa-Cohen Y, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. *Journal of Clinical Investigation* 2021. <https://doi.org/10.1172/JCI150319>.
- [20] Kelly JC, Carter EB, Raghuraman N, Nolan LS, Gong Q, Lewis AN, et al. Anti-SARS-CoV-2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination. *American Journal of Obstetrics and Gynecology* 2021;0. <https://doi.org/10.1016/j.ajog.2021.03.031>.
- [21] Rosenberg-Friedman M, Kigel A, Bahar Y, Werbner M, Alter J, Yogev Y, et al. BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women. *Nat Commun* 2021;12:6222.
- [22] Marks KJ, Whitaker M, Agathis NT, Anglin O, Milucky J, Patel K, et al. Hospitalization of infants and children aged 0-4 years with laboratory-confirmed COVID-19 - COVID-NET, 14 states, March 2020-February 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:429–36.
- [23] Carlsen EØ, Magnus MC, Oakley L, Fell DB, Greve-Isdahl M, Kinge JM, et al. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. *JAMA Intern Med* 2022. <https://doi.org/10.1001/jamainternmed.2022.2442>.
- [24] Halasa NB, Olson SM, Staat MA, Newhams MM, Price AM, Pannaraj PS, et al. Maternal vaccination and risk of hospitalization for Covid-19 among infants. *N Engl J Med* 2022;387:109–19.
- [25] MacMullan MA, Ibrayeva A, Trettner K, Deming L, Das S, Tran F, et al. ELISA detection of SARS-CoV-2 antibodies in saliva. *Sci Rep* 2020;10:20818.
- [26] Kachikis A, Englund JA, Covelli I, Frank Y, Haghghi C, Singleton M, et al. Analysis of vaccine reactions after COVID-19 vaccine booster doses among pregnant and lactating individuals. *JAMA Netw Open* 2022;5:e2230495.
- [27] Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Ietto G, Iovino D, et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. *EBioMedicine* 2022;75:103788.
- [28] Selma-Royo M, Bäuerl C, Mena-Tudela D, Aguilar-Camprubí L, Pérez-Cano FJ, Parra-Llorca A, et al. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study. *Genome Med* 2022;14:42.
- [29] Pannaraj PS, da Costa-Martins AG, Cerini C, Li F, Wong S-S, Singh Y, et al. Molecular alterations in human milk in simulated maternal nasal mucosal infection with live attenuated influenza vaccination. *Mucosal Immunol* 2022. <https://doi.org/10.1038/s41385-022-00537-4>.
- [30] Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Sci Transl Med* 2021;13:eabd2223.
- [31] Tang J, Zeng C, Cox TM, Li C, Son YM, Cheon IS, et al. Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination. *Sci Immunol* 2022:eadd4853.
- [32] Sano K, Bhavsar D, Singh G, Floda D, Srivastava K, Gleason C, et al. SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. *Nat Commun* 2022;13:5135.
- [33] CDC. SARS-CoV-2 variant classifications and definitions. Centers for Disease Control and Prevention 2022. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html?CDC_AA_refVal=https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html (accessed August 17, 2022).

- [34] Prael M, Golan Y, Cassidy AG, Matsui Y, Li L, Alvarenga B, et al. Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy. *Nat Commun* 2022;13:4422.
- [35] Shook LL, Atyeo CG, Yonker LM, Fasano A, Gray KJ, Alter G, et al. Durability of anti-spike antibodies in infants after maternal COVID-19 vaccination or natural infection. *JAMA* 2022;327:1087–9.

Table 1. Sample characteristics, overall and for the 3rd dose subgroups

Demographic and primary vaccine characteristics	Total sample (n=30 ^a)	3 rd dose subgroups	
		Uninfected (n=9)	COVID-19 infection (n=10)
<u>Demographic Characteristics</u>			
Maternal age, years			
Mean (SD)	37.2 (4.1)	37.8 (3.3)	36.3 (4.0)
Median (min, max)	37.2 (29.3, 44.7)	38.0 (31.4, 41.6)	37.3 (29.3, 42.0)
Race/ethnicity, % (n)			
Asian	20% (6)	22% (2)	10% (1)
Black or African American	3% (1)		10% (1)
Hispanic/Latina	3% (1)		
White/Caucasian	70% (21)	67% (6)	80% (8)
More than 1 race/ethnicity	3% (1)	11% (1)	
Education, % (n)			
Some college	3% (1)	11% (1)	
College graduate	23% (7)	22% (2)	40% (4)
Advanced degree	73% (22)	67% (6)	60% (6)
Employed in health care, % (n)			
Yes, providing direct patient care	40% (12)	67% (6)	30% (3)
Yes, but not in direct patient care	13% (4)	11% (1)	20% (2)
No	47% (14)	22% (2)	50% (5)
Number of children, % (n)			
1	47% (14)	56% (5)	40% (4)
2	43% (13)	33% (3)	50% (5)
3	10% (3)	11% (1)	10% (1)
Duration of pregnancy, weeks			
Mean (SD)	39.3 (1.4)	39.3 (1.2)	38.9 (1.8)
Median (min, max)	39.5 (33.9, 41.3)	39.1 (37.4, 41.0)	39.4 (33.9, 40.1)
Infant sex, % (n)			
Male	43% (13)	33% (3)	60% (6)
Female	57% (17)	67% (6)	40% (4)
<u>Primary Maternal COVID-19 Vaccine</u>			
(n=33)			
Manufacturer, % (n)			
Pfizer-BioNTech	61% (20)	67% (6)	40% (4)
Moderna	39% (13)	33% (3)	60% (6)
Timing of 1st dose, % (n)			
During pregnancy	76% (25)	78% (7)	90% (9)
During postpartum period	24% (8)	22% (2)	10% (1)

Notes: ^a The sample size for some variables is reduced due to missing survey data from 3 participants. The 3rd dose subgroups (n=19) did not differ significantly on any variable in this table.

Table 2. Symptoms after 3rd vaccine dose

Symptoms	Total 3rd dose sample (n=26)
Injection site symptoms, % (n)	
Any injection site symptoms	73% (19)
Pain	62% (16)
Redness	4% (1)
Swelling	8% (2)
Itching	-
Rash near injection site	-
General symptoms, % (n)	
Any general symptoms	65% (17)
Fever	12% (3)
Chills	12% (3)
Headache	27% (7)
Joint pain	12% (3)
Muscle/body aches	31% (8)
Fatigue or tiredness	50% (13)
Lump/swelling in breast (opposite side of injection)	4% (1)

Note: Additional symptoms assessed but not reported by any participant after 3rd dose: nausea vomiting, diarrhea, abdominal pain, rash, mastitis, decreased milk supply or other symptom not listed above.

Table 3. Clinical characteristics of participants in the 3rd dose subgroups

Characteristics	3rd dose subgroups	
	Uninfected (n=9)	COVID-19 infection (n=10)
<i>Maternal vaccine-related characteristics</i>		
Third vaccine dose received, % (n)		
BTN162b2 (Pfizer-BioNTech)	44% (4)	30% (3)
mRNA-1273 (Moderna)	56% (5)	70% (7)
Infant age at 3rd dose, months		
Mean (SD)	6.8 (3.7)	4.7 (3.4)
Median (min, max)	5.5 (0.8, 11.9)	5.2 (-1.7 ^a , 9.4)
Days between third dose and symptom assessment		
Mean (SD)	83 (92)	121 (85)
Median (min, max)	42 (15, 260)	91.5 (29, 269)
<i>SARS-CoV-2 infection characteristics^b</i>		
COVID-19 infections, % (n)		
Mother and infant		80% (8)
Mother only		20% (2)
Neither mother nor infant	100% (9)	
Infant age at time of maternal infection, months		
Mean (SD)		7.1 (3.5)
Median (min, max)		7.8 (-0.8 ^a , 12.0)
Days between maternal 3rd dose and infection		
Mean (SD)		72 (38)
Median (min, max)		72 (23, 141)

Notes: The 3rd dose subgroups did not differ significantly on any variable in this table (comparisons exclude the 3 participants included in both subgroups).

^a One infant had a negative age at both the maternal 3rd dose and maternal infection because both occurred during pregnancy, prior to the infant's birth.

^b Of the 10 COVID-19 infections, 2 were diagnosed in late December 2021, 5 in January 2022, 2 in February 2022, and 1 in early March 2022.

Table 4. Comparison of post 3rd dose symptoms and COVID symptoms for participants with COVID-19 infection (n=10 paired analysis)

Symptoms	Timing of symptoms	
	After 3rd dose	During COVID-19 infection
General symptoms		
Any symptoms	50% (5)*	100% (10)*
Fever	20% (2)	30% (3)
Chills	10% (1)	20% (2)
Headache	10% (1)	50% (5)
Muscle/body aches	20% (2)	40% (4)
Fatigue or tiredness	40% (4)	50% (5)
Nausea	-	10% (1)
COVID-specific symptoms		
Sore throat	**	40% (4)
Shortness of breath	**	-
Cough	**	60% (6)
Loss of taste or smell	**	10% (1)
Runny or congested nose	**	80% (8)
Eye redness or discharge	**	-

Note: In this small sample, individual symptom frequencies after 3rd dose and during Omicron infection were not significantly different. Additional symptoms assessed but not reported by any participant either after 3rd dose or during COVID infection: vomiting, diarrhea, abdominal pain, rash, lump/swelling in breast, mastitis, decreased milk supply or other symptom not listed above.

* Symptoms were more likely to be reported during Omicron infection than after the 3rd vaccine dose ($p=.025$ for McNemar's chi-square test).

** COVID-specific symptoms were only assessed after Omicron infection, not after 3rd dose.

Table 5. Infant symptoms after 3rd maternal vaccine dose and during COVID-19 infection

INFANT SYMPTOMS AFTER THIRD MATERNAL VACCINE DOSE	% (n)
None reported among the 26 participants who completed the symptom survey after their third vaccine dose	0% (0)
INFANT SYMPTOMS DURING COVID-19 INFECTION (n=8)	% (n)
Any symptoms	100% (8)
Cough	88% (7)
Runny nose	88% (7)
Fever	50% (4)
Fatigue	25% (2)
Loss of appetite	38% (3)
Eye redness	12% (1)
Diarrhea	12% (1)
Swollen lymph nodes	12% (1)
Joint pain	12% (1)
Muscle/body aches	12% (1)
Other symptoms:	25% (2)
Mildly fussy/woke up more frequently during the night. Mild fever and fussiness/fatigue lasted ~24 hours but runny nose persisted for a week	
Mild increased work of breathing and mild tachypnea	
TREATMENT FOR INFANT COVID INFECTION (n=8)	
Consulted with pediatrician regarding COVID-19 infection	88% (7)
Treated with anti-pyretics	12% (1)
Evaluated in Emergency Department for COVID-19 infection	12% (1)
Infant was hospitalized for COVID-19 Infection	-

Symptoms asked about, but not reported for any infant: rash, hand or foot swelling, redness of tongue, shortness of breath, chest discomfort/pain, loss of taste or smell, headache, dizziness, vertigo, insomnia, hair loss, persistent sweating, impaired memory, poor concentration.




Figure 1: Comparison of symptoms reported by participants after 1st, 2nd and 3rd mRNA-based vaccine. Fisher's Exact test for independent samples was performed to compare symptoms reported after 3rd dose to those reported after 1st and 2nd dose in lactating individuals, as previously reported [12]. Asterisks indicate symptoms significantly different between 2nd and 3rd dose (p-value <0.01). No significant differences were observed between 1st and 3rd dose.




Figure 2: Anti-Spike antibodies response to vaccination and infection. Anti-Spike IgG (A) and IgA (B) were measured in human milk samples and IgA was measured in serum samples (C) by ELISA, at multiple time points as represented in the X axis. Samples collected before any COVID-19 vaccine administration (pre), 41±8 days after the 2nd dose (post 2nd), 223±36 days after the 2nd dose (pre-boost), 42±15 days post 3rd dose (post 3rd) and 142±10 days post the 3rd dose (long post 3rd) and 36±15 days post infection with SARS-CoV-2 (post infection).

Dotted lines indicate the lower cut-off (above 1 considered positive). Upper limit of detection was at a ratio of 8.5. Asterisks represent p-values: * = p-value <0.05, ** = p-value <0.01, *** = <0.001, **** = <0.0001 as determined by unpaired Mann-Whitney test. D) Two-tailed Spearman correlation was used to correlate milk and serum anti-Spike IgA levels at Post-Dose 3 (triangles) and Post infection (circles).




Figure 3: Maternal saliva antibodies response and presence of milk antibodies in infant saliva after feeding. Two-tailed Spearman correlation was used to correlate milk and maternal saliva anti-Spike IgA levels (A) and IgG (B). In addition, anti-Spike IgA levels (C) and IgG (D) infant saliva samples were measured at multiple time points, immediately after breastfeeding (0), 30 minutes (30 min) after feeding, 1 hour after feeding (1 hr) and before next feeding (2-3 hours after feeding). Maternal saliva was collected at the same day for comparison. Dotted lines indicate the lower cut-off (above 1 considered positive).